In addition, PRMT5 is heterogeneously expressed in triple-negative breast cancer (TNBC); and inhibition of PRMT5 triggers apoptosis and regulates cell cycle progression (Vinet et al., 2019). Here, PRMT5 is linked to triple-negative breast carcinoma.